when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Oncology · news · pharmadog

← back to Oncology

News · Oncology

910 stories

Jul 22, 26Summit and Akeso sharpen case for ivonescimab with new Western databiospace

Jul 22, 26NIH joins Trump’s $5B AI mission with biomedical research pushfiercebiotech

Jul 22, 26STAT+: Pharma tries to tamp down broad China restrictionsstat

Jul 22, 26Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studybiopharma dive

Jul 22, 266 companies hiring in Cambridge nowbiospace

Jul 22, 26Summit reports two-year survival data for Western patients, though context lackingendpoints

Jul 22, 26Novartis scraps mid-stage radiopharma asset as Pluvicto soarsbiospace

Jul 22, 26As Maui recovers from devastating fires, a study offers vision for new rural health modelstat

Jul 22, 26AI data becomes sticking point in biopharma dealmakingbiospace

Jul 22, 26Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsbiospace

Jul 21, 26‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraisefiercebiotech

Jul 21, 26Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’biopharma dive

Jul 21, 26Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsbiospace

Jul 21, 26‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealfiercebiotech

Jul 21, 26Axiom plans Hong Kong IPO, hoping to carve new path for US biotechsbiospace

Jul 21, 26Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’fiercebiotech

Jul 21, 26Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assetsfiercebiotech

Jul 20, 26Tempus to acquire cancer test maker Personalis for $1.5Bbiopharma dive

Jul 20, 26Tempus to buy cancer test-maker Personalis for $1.5Bbiopharma dive

Jul 20, 26Pain drugmaker Latigo outlines plans to go publicbiopharma dive

Jul 20, 26HHS vaccine committee quietly gets new charterstat

Jul 20, 26STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputerstat

Jul 20, 26Tempus buys out cancer genomics partner Personalis in $1.5 billion dealfiercebiotech

Jul 20, 26BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’fiercebiotech

Jul 20, 26Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independencebiospace

Jul 20, 26How Kyverna rode CAR T’s autoimmune wave to the FDA’s doorbiospace

Jul 20, 26Recon: BMS to construct AI supercomputer with Nividia; Tempus to acquire cancer diagnostic maker Personalis for $1.5Braps

Jul 20, 26Study: China outpaces the US in cancer approvals, lags behind on first approvalsraps

Jul 20, 26MHRA touts uptick in approvals in 2025-2026 annual reportraps

Jul 19, 26Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journaxfiercebiotech

← prevpage 11 of 31next →